PharmacoEconomics

, Volume 13, Issue 4, pp 435–448 | Cite as

Antidepressant Selection and Use and Healthcare Expenditures

An Empirical Approach
  • William H. Crown
  • Timothy R. Hylan
  • Laurie Meneades
Original Research Article Antidepressant Selection/Use and Healthcare Expenditures

Summary

The purpose of this study was to evaluate whether 1−year total healthcare expenditures differed between patients who initiated therapy on a tricyclic antidepressant (TCA) or a selective serotonin reuptake inhibitor (SSRI) after controlling for initial antidepressant selection and antidepressant use pattern. A retrospective claims database covering a privately insured population in the US was used. Patients who initiated therapy in the outpatient setting (primary care or psychiatrist) were considered. Two—stage sample selection models were estimated that included controls for initial antidepressant selection and use pattern. The analyses indicated that: (i) self—selection due to initial antidepressant selection was a statistically significant determinant of expenditures for patients who initiated therapy on a TCA but not an SSRI; (ii) after controlling for initial antidepressant selection, antidepressant use pattern was a statistically significant and positive determinant of expenditures for both TCA and SSRI patients; and (iii) after controlling for initial antidepressant selection and use pattern, 1−year total direct healthcare expenditures were significantly lower for patients who initiated therapy on an SSRI than for patients who initiated therapy on a TCA.

Keywords

Adis International Limited Ordinary Little Square Selective Serotonin Reuptake Inhibitor Healthcare Expenditure Sample Selection Model 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996; 275 (24): 1897–902PubMedCrossRefGoogle Scholar
  2. 2.
    Heckman JJ, Smith JA. Assessing the case for social experiments. J Econ Perspect 1995; 9 (2): 85–110CrossRefGoogle Scholar
  3. 3.
    Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998; 13 (1 Pt 1): 61–70PubMedCrossRefGoogle Scholar
  4. 4.
    Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48 (11): 1420–6PubMedGoogle Scholar
  5. 5.
    Hylan TR, Crown WH, Meneades L, et al. TCA and SSRI antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71–9PubMedCrossRefGoogle Scholar
  6. 6.
    Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1–11PubMedCrossRefGoogle Scholar
  7. 7.
    Sturm R, Wells K. How can care for depression become more cost—effective? JAMA 1995; 273 (1): 51–8PubMedCrossRefGoogle Scholar
  8. 8.
    Mintz J, Mintz LI, Arruda MJ, et. al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49 (10): 761–8PubMedCrossRefGoogle Scholar
  9. 9.
    Agency for Health Care Policy Research (AHCPR). Treatment of major depression: clinical practice guidelines no. 5, vol. 2. Rockville (MD): US Department of Health and Human Services, 1993. AHCPR publication no.: 93-0550Google Scholar
  10. 10.
    Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30 (1): 67–76PubMedCrossRefGoogle Scholar
  11. 11.
    Simon G, Von Korff M, Wagner EH, et. al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993; 15 (6): 399–408PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson D. Noncompliance with antidepressant therapy: an underestimated problem. Intern Med 1986; 11: 14–7Google Scholar
  13. 13.
    Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients’ adherence to antidepressant therapy. Med Care 1995; 33 (1): 67–74PubMedCrossRefGoogle Scholar
  14. 14.
    Thompson D, Buesching D, Gregor K, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996; 2 (9): 1239–46Google Scholar
  15. 15.
    Murnane R, Newstead S, Olsen R. Comparing public and private schools: the puzzling role of selectivity bias. J Econ Bus Stat 1985; 3 (1): 23–35Google Scholar
  16. 16.
    Heckman J. The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models. Ann Econ Soc Meas 1976; 5: 475–92Google Scholar
  17. 17.
    Heckman J. Sample selection as a specification error. Econometrica 1979; 47 (1): 153–61CrossRefGoogle Scholar
  18. 18.
    Maddala GS. Introduction to econometrics. New York: Macmillan Publishing Co., 1988Google Scholar
  19. 19.
    Greene WH. Limdep [computer program]. Vol. 7. New York: Econometric Software; 1995Google Scholar
  20. 20.
    Obenchain RL, Melfi CA, Croghan TW, et al. Bootstrap analyses of cost—effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics 1997; 11 (5): 464–72PubMedCrossRefGoogle Scholar
  21. 21.
    Maddala GS. Limited and dependent and qualitative variables in econometrics. Cambridge: Cambridge University Press, 1983Google Scholar
  22. 22.
    Maddala GS, Lee LF. Recursive models with qualitative endogenous variables. Ann Econ Soc Meas 1976; 5 (4): 525–45Google Scholar
  23. 23.
    Greene WH. Econometric analysis. New York: MacMillan Publishing Company, 1993Google Scholar
  24. 24.
    Skaer TL, Sclar DA, Robison L, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995; 56 (6): 556–67CrossRefGoogle Scholar
  25. 25.
    Sclar DA, Robison LM, Skaer TL, et. al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16 (4): 715–30PubMedGoogle Scholar
  26. 26.
    Sclar DA, Robison LM, Skaer T, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res 1995; 23: 395–412PubMedGoogle Scholar
  27. 27.
    Henk H, Katzelnick DJ, Kobak KA, et al. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry 1996; 53 (10): 899–904PubMedCrossRefGoogle Scholar
  28. 28.
    Simon GE, Von Korff M, Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152 (3): 352–7PubMedGoogle Scholar
  29. 29.
    Song F, Freemantle N, Sheldon TA, et. al. Selective serotonin reuptake inhibitors: meta—analysis of efficacy and acceptability, BMJ 1993: 306: 683–7PubMedCrossRefGoogle Scholar
  30. 30.
    Woods S, Rizzo J. Cost—effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997; 170: 257–63PubMedCrossRefGoogle Scholar
  31. 31.
    Simon GE, Von Korff M. Recognition, management and outcomes of depression in primary care. Arch Fam Med 1995; 4 (2): 99–105PubMedCrossRefGoogle Scholar
  32. 32.
    Rost K, Smith GR, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3: 333–7PubMedCrossRefGoogle Scholar
  33. 33.
    Gregor K, Overhage JM, Coon SJ, et. al. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin Ther 1994; 16 (2): 306–15PubMedGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • William H. Crown
    • 1
  • Timothy R. Hylan
    • 2
    • 3
  • Laurie Meneades
    • 1
  1. 1.The MEDSTAT GroupCambridgeUSA
  2. 2.Global Health Economics Research, drop code 2646, Lilly Corporate CenterEli Lilly and CompanyIndianapolisUSA
  3. 3.School of Public and Environmental AffairsIndiana UniversityIndianapolisUSA

Personalised recommendations